+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts



Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts



Bjog 112(8): 1121-1125



To compare the efficacy and tolerability of the levonorgestrel intrauterine system (LNG IUS) with mefenamic acid in the management of objective idiopathic menorrhagia. Phase III, Single centre, open, randomised, comparative, parallel group study. District General Hospital in the United Kingdom. Fifty-one women with objective menorrhagia. Twenty-five women randomised to receive the LNG IUS and 26 to oral mefenamic acid for six cycles. Change from baseline in menstrual blood loss (MBL), total menstrual fluid loss (TMFL) and pictorial blood loss assessment chart (PBAC) score at the third and sixth cycle of treatment. After six cycles the median menstrual blood loss was 5 mL in the LNG IUS group and 100 mL in the mefenamic acid group (P < 0.001). Median TMFL was 27 mL in the LNG IUS group and 157 mL in the mefenamic acid group (P < 0.001). Median PBAC score was 25 in the LNG IUS group and 159 in the mefenamic acid group. Changes in menstrual blood loss correlated strongly to changes in TMFL (r= 0.88) but PBAC correlated less well to blood loss and total fluid loss (r= 0.53 and r= 0.58). Both the LNG IUS and mefenamic acid significantly decreased menstrual blood loss, TMFL and PBAC scores. The LNG IUS produced greater reductions in all parameters than mefenamic acid. Comparison of the different measurements suggests that TMFL assessment may be an easier and a more relevant measure of symptom severity than menstrual blood loss.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 050109999

Download citation: RISBibTeXText

PMID: 16045528

DOI: 10.1111/j.1471-0528.2005.00642.x


Related references

Randomised Comparative Trial of the Levonorgestrel Intrauterine System and Mefenamic Acid for the Treatment of Idiopathic Menorrhagia: A Multiple Analysis Using Total Menstrual Fluid Loss, Menstrual Blood Loss, and Pictorial Blood Loss Assessment Charts. Obstetrical & Gynecological Survey 60(11): 727-728, 2005

Assessment of menstrual blood loss in women with ideopathic menorrhagia using the frameless levonorgestrel-releasing intrauterine system. Contraception 70(2): 165-168, 2004

The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagia. Journal of Thrombosis and Haemostasis 5(1): 133-138, 2006

Assessment of menstrual blood loss in Belgian users of a new T-shaped levonorgestrel-releasing intrauterine system. Contraception 71(6): 470-473, 2005

Reduction of mefenamic acid of increased menstrual blood loss associated with intrauterine contraception. British Journal of Obstetrics and Gynaecology 85(1): 53-62, 1978

Pictorial blood loss assessment chart for quantification of menstrual blood loss: a systematic review. Gynecological Surgery 12(3): 157-163, 2015

Levonorgestrel-intrauterine system effects on hemostasis and menstrual blood loss in women seeking contraception. Journal of Obstetrics and Gynaecology Research 36(4): 838-844, 2010

Assessment of menorrhagia by total menstrual fluid loss. Journal of Obstetrics and Gynaecology 26(5): 438-441, 2006

Menstrual blood loss with levonorgestrel nova t and multiload copper 250 intrauterine device. Advances in Contraception 1(3): 245, 1985

The effect on menstrual blood loss in women with uterine fibroids of a novel "frameless" intrauterine levonorgestrel-releasing drug delivery system: a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology 102(1): 74-79, 2002

Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. British Journal of Obstetrics and Gynaecology 105(6): 592-598, 1998

Physiologic studies of menstrual blood loss. I. Range and consistency of menstrual blood loss in and iron requirements of menstruating Egyptian women. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics 17(4): 343-348, 1980

Assessment of menstrual blood loss using a pictorial chart. British Journal of Obstetrics & Gynaecology 97(8): 734-739, 1990

The effects of mefenamic acid and norethisterone on measured menstrual blood loss. Obstetrics and Gynecology 76(1): 85-88, 1990

Reduction of menstrual blood loss in women suffering from idiopathic menorrhagia with a novel antifibrinolytic drug (Kabi 2161). British Journal of Obstetrics and Gynaecology 102(11): 913-917, 1995